TNFRSF17 and hematologic disorder: Due to their prominent therapeutic effects in many hematological malignancies, the US Food and Drug Administration (FDA) has approved six kinds of drugs for B-cell maturation antigen (BCMA) hitherto (Schuster et al., 2017; Abramson et al., 2020; Raychaudhuri et al., 2020; Khurana et al., 2021; Si Lim et al., 2021; Ying et al., 2021).